Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Lazzeri
Massimo
M
D000083:Acetanilides / Q000627:therapeutic use; D058667:Adrenergic beta-3 Receptor Agonists; D000818:Animals; D000077608:Aprepitant; D005260:Female; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage*; D018040:Receptors, Neurokinin-1 / Q000187:drug effects; D013844:Thiazoles / Q000627:therapeutic use; D001743:Urinary Bladder / Q000187:drug effects / Q000294:innervation / Q000473:pathology; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy* / Q000209:etiology; D014563:Urodynamics / Q000187:drug effects
D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D009025:Morpholines; D011720:Pyrazoles; D018040:Receptors, Neurokinin-1; D013844:Thiazoles; D000077608:Aprepitant; C520025:mirabegron; C075798:cizolirtine